Open house Arzneimittelrabattverträge Airpiprazol Depot-Injektionssuspension
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Airpiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed minimum volumes; financial return is uncertain.
The open-house model is not subject to procurement law, but the notice includes a voluntary standstill period of 10 day...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Non-exclusive rebate agreements for Aripiprazole depot injection suspension (ATC N05AX12) under §130a Abs. 8 SGB V.
- All interested pharmaceutical companies can conclude identical, non-negotiable rebate agreements.
Show full summary
This is an open-house model (not a competitive procurement) by AOK Bayern to conclude non-exclusive rebate agreements with all interested pharmaceutical companies for the active ingredient Aripiprazole in depot injection suspension (ATC N05AX12). Any eligible pharmaceutical company can join at any time during the contract period (01.09.2025 to 31.08.2027), with the final deadline for signing 03.07.2027. No estimated value is provided. The procedure is not subject to procurement law. Only the structured data and TED XML notice were analyzed; no procurement documents were examined.
Risks
No estimated value or guaranteed minimum volumes; financial return is uncertain.
The open-house model is not subject to procurement law, but the notice includes a voluntary standstill period of 10 day...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer).
Administrative
- Submit signed and completed self-declaration of reliability.
- Submit signed contract and annex listing the medicinal products.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Airpiprazol Depot-Injektionssuspension
Non-exclusive rebate agreement for Aripiprazole depot injection suspension (ATC N05AX12) with AOK Bayern. Any pharmaceutical company meeting eligibility can join. Contract period 01.09.2025-31.08.2027, with possible termination. No estimated value.
Location
Duration
Category
Award Criteria
Award details
No award criteria
all eligible companies are accepted.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Airpiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 456665-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed minimum volumes; financial return is uncertain.
The open-house model is not subject to procurement law, but the notice includes a voluntary standstill period of 10 day...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications